Investigational drug · Phase 3
DA-5219
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastritis Acute, Gastritis Chronic.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "DA-5219"
First trial start
2024
Jan 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DA-5219", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastritis Acute
- Gastritis Chronic
Largest trials
Live from ClinicalTrials.gov: studies naming "DA-5219" as an intervention, largest first.
- Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic GastritisPivotal-lookingCompleted
Dong-A ST Co., Ltd.Industry
NCT06151210 · 467 participants · Start Jan 31, 2024 · Primary completion Jul 10, 2025
Drug: DA-5219; Stillen® Tab and 2 more · For: Gastritis Acute; Gastritis Chronic
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.